| Sep 24 |
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
|
| Sep 19 |
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
|
| Sep 16 |
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
|
| Sep 12 |
Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives
|
| Sep 11 |
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
|
| Sep 11 |
Supernus cut to Neutral at Piper Sandler on Qelbree growth trajectory
|
| Sep 11 |
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
|
| Aug 28 |
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
|
| Aug 19 |
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
|
| Aug 14 |
Some May Be Optimistic About Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings
|
